-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MwMqh8hwESFgN5LVSCJPHK2T65UA+Rx1g5d0pTtkSK1d4Tryn5AVYBryBdvBHKaT
 Ut08ANL/TBnQZ14XuKFHaw==

<SEC-DOCUMENT>0001140361-09-021819.txt : 20090928
<SEC-HEADER>0001140361-09-021819.hdr.sgml : 20090928
<ACCEPTANCE-DATETIME>20090928132043
ACCESSION NUMBER:		0001140361-09-021819
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20090924
FILED AS OF DATE:		20090928
DATE AS OF CHANGE:		20090928

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			CAVAZZA CLAUDIO
		CENTRAL INDEX KEY:			0001164803

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-16929
		FILM NUMBER:		091089716

	MAIL ADDRESS:	
		STREET 1:		VIA SUDAFRICA 20
		CITY:			ROME ITALY
		STATE:			L6
		ZIP:			00000

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DOR BIOPHARMA INC
		CENTRAL INDEX KEY:			0000812796
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				411505029
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		29 EMMONS DRIVE
		STREET 2:		SUITE C-10
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
		BUSINESS PHONE:		609-452-0001

	MAIL ADDRESS:	
		STREET 1:		29 EMMONS DRIVE
		STREET 2:		SUITE C-10
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ENDOREX CORP
		DATE OF NAME CHANGE:	19960916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc1.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0303</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2009-09-24</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000812796</issuerCik>
        <issuerName>DOR BIOPHARMA INC</issuerName>
        <issuerTradingSymbol>DORB</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001164803</rptOwnerCik>
            <rptOwnerName>CAVAZZA CLAUDIO</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>VIA SUDAFRICA, 20</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>ROME</rptOwnerCity>
            <rptOwnerState>L6</rptOwnerState>
            <rptOwnerZipCode>00144</rptOwnerZipCode>
            <rptOwnerStateDescription>ITALY</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2009-09-24</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>3952569</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.253</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>45619236</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                    <footnoteId id="F1"/>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>Indirect</value>
                    <footnoteId id="F1"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Common Stock Warrant (warrant to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.278</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2009-09-24</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>J</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F2"/>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>1</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <value>2009-09-27</value>
            </exerciseDate>
            <expirationDate>
                <value>2014-09-27</value>
                <footnoteId id="F3"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>1976284</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                    <footnoteId id="F2"/>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>Indirect</value>
                    <footnoteId id="F2"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Shares directly owned by Sigma-Tau Pharmaceuticals, Inc. (?Pharmaceuticals?).  Pharmaceuticals is a direct wholly-owned subsidiary of Sigma-Tau America S.A. (?America?).  America is a direct wholly-owned subsidiary of Sigma-Tau International S.A. (?International?).  International is a direct wholly-owned subsidiary of Sigma-Tau Finanziaria S.p.A. (&quot;Sigma Tau&quot;).  Claudio Cavazza directly and indirectly owns 57% of Sigma Tau.</footnote>
        <footnote id="F2">This warrant was issued by the Issuer to Pharmaceuticals in consideration of Pharmaceuticals? purchase of 3,952,569 shares of common  stock on September 24, 2009.</footnote>
        <footnote id="F3">The expiration date of the warrant may be accelerated at the Issuer?s option if the Issuer?s common stock meets certain price thresholds and the common shares underlying the warrant are registered for resale pursuant to an effective registration statement or are freely transferable without volume restrictions pursuant to Rule 144 under the Securities Act of 1933, as amended.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Maurizio Terenzi, Proxy-holder authorized</signatureName>
        <signatureDate>2009-09-28</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----